Lung-cOnservative Liquid VEntilation for the Induction of Ultra-Rapid COOLing After Cardiac Arrest
A legfontosabb adatok
- Ki végzi
- ORIXHA
- Hol
- Franciaország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 24 fő, tervezett
- Kezdés
- 2025. márc.
- Tervezett befejezés
- 2026. márc.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Ultra-rapid therapeutic hypothermia induction by total liquid ventilation
- A regiszteradat frissítve
- 2025. január 29.
Ki vehet részt
- Életkor
- 18 év – 84 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Patient resuscitated after extra- or intra-hospital cardiac arrest, from presumed cardiac or asphyxial origin, regardless of the heart rate initially recorded
- Age between 18 and 84 years old
- Time between collapse and return of spontaneous circulation (ROSC) < 60 min
- Presumption, at the time of inclusion, of a possibility of starting Vent2Cool within a period of less than 120 min after ROSC
- Unconscious (GCS <8, not able to obey verbal commands after sustained ROSC)
- Patient affiliated with a social security system (If applicable)
- Consent of the member of patients' family or that of the trusted person if present and able to understand; otherwise certificate of emergency inclusion in compliance with applicable regulations
- Vent2Cool must be connected to a standard cuffed ETT of 7.0 mm to 9.0 mm internal diameter for the procedure
Ki nem vehet részt
- Traumatic cardiac arrest, drowning, exsanguination, or sepsis
- Need for veno-arterial extracorporeal circulation (Extracorporeal membrane of oxygenation, ECMO) before return of spontaneous circulation (refractory cardiac arrest)
- Suspicion of intracranial bleeding
- History of severe Chronic Obstructive Pulmonary Disease (COPD) with long-term home oxygen therapy
- Acute respiratory pathology (pneumothorax, pleurisy, pneumonia, suspicion of contusion or intra-pulmonary hemorrhage following resuscitation)
- COVID-19 positive test in case of clinical suspicion and/or epidemic context
- Women under 50 years old (childbearing age) or for women of >50 years old, a positive pregnancy test (urinary) in case of pregnancy suspicion by the investigator. Possible breastfeeding during the study
- Conscious patient
- Patient Ideal Body Weight less than 40 kgs or more than 93 kgs
- Temperature at admission < 34.0°C
- One of the following signs at echocardiography at hospital admission:; Acute cor pulmonale, defined by right ventricular enlargement with interventricular septal deviation, associated with a Tricuspid Annular Plane Systolic Excursion (TAPSE) < 12 mm and need for vasopressor agents; Time-velocity integral of subaortic flow < 10 m/s
- Wrong positioning or damage of the endotracheal tube
- Excessive mucus in the upper airways
- Patient presenting at least one of the following criteria in the mechanical ventilation parameters at inclusion:; PEEP > 8 cm H2O; Plateau pressure> 25 cmH2O; Driving pressure> 15cmH2O
- Patient with at least one of the following criteria at inclusion:; PaO2< 80 mmHg; PaO2 / FiO2< 150 mmHg; PaCO2> 48 mmHg
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 84 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Out-of-hospital cardiac arrest (OHCA) affects over 356,000 individuals annually in the United States, with fewer than 10% surviving to hospital discharge, mirroring statistics from Europe. Post-cardiac arrest syndrome (PCAS), a condition causing multi-organ dysfunction, is a leading cause of mortality despite successful resuscitation efforts. Targeted temperature management (TTM) is recommended for comatose patients post-resuscitation to mitigate PCAS, but optimal temperature targets and cooling methods remain unclear. Experimental studies suggest that therapeutic hypothermia (32-34°C), induced rapidly after resuscitation, may provide significant clinical benefits.
A teljes eredeti leírásKevesebb
Total liquid ventilation (TLV) with breathable liquids has been proposed to achieve ultra-rapid therapeutic hypothermia (URTH). This approach uses the lungs as a heat exchanger to achieve ultra-rapid cooling while maintaining normal gas exchange. It enables a reduction in core body temperature to the hypothermic range (33.0 ± 0.5°C) within 45 minutes in relevant experimental models.
The OverCool study is an open-label, single-arm, multi-centric pilot trial designed to evaluate the performance and safety of Vent2Cool, a medical device intended to induce ultra-rapid therapeutic hypothermia by TLV in resuscitated cardiac arrest patients. The primary objective is to demonstrate Vent2Cool's ability to achieve a target core temperature of 33.0 ± 0.5°C within 60 minutes from start of procedure in resuscitated patients admitted to the Intensive Care Unit following intra- or extra-hospital cardiac arrest. Secondary objectives include assessing procedural safety, cooling performance, feasibility in emergency settings, clinical outcomes, and the impact on biological markers.
A vizsgálat csoportja
- Treatment with Vent2Cool deviceA vizsgált kezelés
Vent2Cool is to be used to perform induction of Ultra-Rapid Therapeutic Hypothermia for the patients. The hypothermia maintenance and rewarming phases will be performed with an external TTM device as currently used in the investigation centres.
Kezelés: Ultra-rapid therapeutic hypothermia induction by total liquid ventilation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Kérdések a feltételekről
- Forrás: NCT06798818: ki vehet részt
- A regiszteradat frissítve
- 2025. január 29.